I'm LongbridgeAI, I can summarize articles.Compass Therapeutics (CMPX) highlighted promising Phase 2/3 data for its lead drug tovecimig in biliary tract cancer, showing superior response rates with paclitaxel. The company outlined plans for late-stage development and potential commercialization, with a cash runway into 2028. While analysts maintain a 'Buy' rating with a $7 target, TipRanks' AI tool rates the stock as 'Neutral' due to pre-revenue status and persistent losses, despite positive clinical news.
Compass Therapeutics ( (CMPX) ) has shared an announcement.
On July 1, 2026, Compass Therapeutics updated its corporate presentation to highlight new data from the COMPANION-002 Phase 2/3 trial of its lead drug candidate tovecimig in second-line biliary tract cancer, where the combination of tovecimig and paclitaxel achieved a significantly higher overall response rate than paclitaxel alone in a 168-patient study. The company detailed a late-stage development and regulatory plan for tovecimig, supported by prior monotherapy and combination data in multiple refractory tumor types, and outlined a diversified oncology pipeline and cash runway into 2028 as it prepares for potential commercialization and multiple clinical milestones over 2026–2027.
The most recent analyst rating on (CMPX) stock is a Buy
with a $7.00 price target.
To see the full list of analyst forecasts on Compass Therapeutics stock,
see the CMPX Stock Forecast page.
Spark’s Take on CMPX Stock
According to Spark, TipRanks’ AI Analyst, CMPX is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue status, persistent losses, and continued cash burn) and a technically weak price trend below major moving averages. Positive clinical-trial news provides a meaningful offset, but current unprofitability (negative P/E) and lack of dividend support keep the overall profile speculative.
To see Spark’s full report on CMPX stock,
click here.
More about Compass Therapeutics
Compass Therapeutics, Inc. is a biotechnology company focused on developing next-generation oncology therapies, notably bispecific antibodies and other immune-oncology agents. Its lead asset, tovecimig, is a DLL4 x VEGF-A bispecific antibody positioned as a next-generation angiogenesis inhibitor, targeting solid tumors including biliary tract cancer and other gastrointestinal and gynecologic malignancies.
Average Trading Volume: 8,132,722
Technical Sentiment Signal: Sell
Current Market Cap: $394.4M
Find detailed analytics on CMPX stock on TipRanks’ Stock Analysis page.